Neuronetics develops and commercializes NeuroStar, an FDA-cleared non-invasive transcranial magnetic stimulation system that treats major depressive disorder, obsessive-compulsive disorder, and related conditions by stimulating specific brain areas associated with mood regulation. The company generates revenue through three primary channels: operating treatment centers that provide TMS therapy sessions to patients, selling capital equipment systems to psychiatric practices and treatment providers, and offering service contracts and extended warranties. The company also owns and operates Greenbrook Treatment Centers, a network of treatment facilities across the United States that administer TMS and esketamine therapy. Neuronetics markets primarily to psychiatrists and other mental health providers, supported by extensive clinical data demonstrating safety and efficacy, and competes on the basis of clinical evidence, system precision, practice management software, and reimbursement expertise.